Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

Aclaris' stock has dropped nearly 70% since September 2023, reflecting its history of failures and dissipations. Explore more ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Out-of-pocket costs are the costs that Medicare does not ... The Food and Drug Administration (FDA) has approved the biologic drug dupilumab (Dupixent). Doctors prescribe it for people with ...

HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...

Dupilumab is suggested for individuals aged ... “For all treatments, cost and insurance coverage should be considered on an individual basis because there are scant cost-effectiveness data ...

That's less than the cost of other biologics for severe asthma like GlaxoSmithKline's IL-5 inhibitor Nucala (mepolizumab) and Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab ...

In terms of biologic treatments, dupilumab is recommended for ages 12 ... differ so much (with delivery and daily use, monitoring, cost), electing EoE treatment is an ideal opportunity for shared ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

These results reflect our ability to drive strong growth, while investing for the future and while carefully managing our cost base at ... with a broad label, the dupilumab with Type 2 ...

but that crown was snatched by Sanofi and Regeneron’s injectable antibody Dupixent (dupilumab), which was approved for the condition in 2022. Faced with the cost of a second trial, the Japanese ...